Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Leases (2016 - 2025)

Historic Capital Leases for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Q3 2025 value amounting to $40000.0.

  • Lineage Cell Therapeutics' Capital Leases fell 5000.0% to $40000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $40000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $67000.0 for FY2024, which is 2637.36% down from last year.
  • Lineage Cell Therapeutics' Capital Leases amounted to $40000.0 in Q3 2025, which was down 5000.0% from $48000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Capital Leases peaked at $133000.0 during Q1 2023, and registered a low of $12000.0 during Q3 2021.
  • In the last 5 years, Lineage Cell Therapeutics' Capital Leases had a median value of $51000.0 in 2025 and averaged $57684.2.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Capital Leases crashed by 7419.35% in 2021, and later soared by 50625.0% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Capital Leases (Quarter) stood at $30000.0 in 2021, then soared by 180.0% to $84000.0 in 2022, then increased by 8.33% to $91000.0 in 2023, then decreased by 26.37% to $67000.0 in 2024, then tumbled by 40.3% to $40000.0 in 2025.
  • Its last three reported values are $40000.0 in Q3 2025, $48000.0 for Q2 2025, and $51000.0 during Q1 2025.